These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37027445)

  • 1. Effect of intra-operative chemotherapy with 5-fluorouracil and leucovorin on the survival of patients with colorectal cancer after radical surgery: a retrospective cohort study.
    Hu X; Zheng Z; Han J; Li B; Guo G; Guo P; Yang Y; Li D; Yan Y; Niu W; Zhou C; Meng Z; Feng J; Yu B; Liu Q; Wang G
    Chin Med J (Engl); 2023 Apr; 136(7):830-839. PubMed ID: 37027445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer.
    Shang A; Wang S; Yang Y; Li L; Zhao Z; Li D; Guo Y; Wang M
    World J Surg Oncol; 2021 Mar; 19(1):84. PubMed ID: 33752702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience.
    Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A
    Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
    Elshenawy MA; Badran A; Aljubran A; Alzahrani A; Rauf MS; Eldali A; Bazarbashi S
    World J Surg Oncol; 2020 Jul; 18(1):163. PubMed ID: 32641137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    Lin L; Zhang Z; Zhang W; Wang L; Wang J
    Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
    Huang WW; Hsieh KP; Huang RY; Yang YH
    Kaohsiung J Med Sci; 2017 Jun; 33(6):308-314. PubMed ID: 28601236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study.
    Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P
    Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
    Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
    Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-320e is a novel prognostic biomarker in colorectal cancer.
    Perez-Carbonell L; Sinicrope FA; Alberts SR; Oberg AL; Balaguer F; Castells A; Boland CR; Goel A
    Br J Cancer; 2015 Jun; 113(1):83-90. PubMed ID: 26035698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
    Baretti M; Rimassa L; Personeni N; Giordano L; Tronconi MC; Pressiani T; Bozzarelli S; Santoro A
    Clin Colorectal Cancer; 2018 Sep; 17(3):e489-e498. PubMed ID: 29650416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
    Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative Chemotherapy with a Novel Regimen Improved the Therapeutic Outcomes of Colorectal Cancer.
    Liu Z; Zou Y; Rong Y; Shi X; Li C; Li C; Tian Y; Lin H; Liu M; Weng J; Liu T; Li X; Lei C; Li W; Zhou X
    J Cancer; 2019; 10(24):5986-5991. PubMed ID: 31762808
    [No Abstract]   [Full Text] [Related]  

  • 18. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
    Rahbari NN; Reissfelder C; Schulze-Bergkamen H; Jäger D; Büchler MW; Weitz J; Koch M
    BMC Cancer; 2014 Mar; 14():174. PubMed ID: 24612620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.